Member Info for nursesteve

My thinking was for maximum news coverage over the weekend (and to create a bit of a buzz?) - maybe it was just Big Al that said that was the way to go?

👍🏻 VS that’s what I’m thinking GL

From 1st June RNS. Chris -

"We look forward to presenting further data updates from this trial later in June, at the BIO International Convention." So we should find out about how the other indications are responding in the AVA6000 trial tomorrow.

I'm especially looking forward to the update on TNBC! An indication Dox is usually used for! & one that might capture main stream news (e.g. no hair loss with latest cancer treatment?). I’m fairly sure Chris said something about this being a reason to target TNBC a while back.

GLA

Thanks HarChris! GL

HarChris (and others) when do you think we will hear what’s going on in those indications? This coming conference?

AJ Bell has it at 192:50 and market closed. 🤨

Probably be better switching to an IG account!

Thanks Amers

Thanks that good to know Amers but where are you seeing the price ?

While the data on SGC is welcome it’s worth remembering that although doxorubicin is a broad-spectrum chemotherapy drug approved for many malignancies, it is primarily used to treat breast cancer and lymphomas. So the results in TNBC could and likely will be much better than the minor and partial responses and 90% disease control rate already seen with SGC. Wonder when we will hear about them? 🤔

GLA

Looks like it will smash through 200 today! GLA

Don’t know how I made it onto that list but I’m in good company! Note IFA90 is on their own filter list! 😂

Space x seems to be taking off! 😜

Looks like HarChris was right about that pattern of a dip in SP after a placing and then an increase about a week later. GLA

Yes I was surprised it dipped below 70p as I thought that would be the floor from now on. Might just have been MM making a play first more shares?

90% disease control rate in SGC. Further data promised for 22 June. Could be data on the other indications? Selling before then is a classic case of ‘taking money from the impatient to give to the patient’. Richard taking over on that date - I don’t see him timing it with anything but good news. GLA

B2HS2L - seems a bit of a strange answer?

Harking back to Dr Tap’s statement about replacing Dox overnight and looking at how they chose to answer that question (by introducing and answering a question on accelerated approval) it could be they are waiting for signs of efficacy on other cancer indications? (Other than SGC). Some of that data could land in under two weeks.

Remember accelerated approval isn’t initiated by the FDA - it has to be applied for by the company. 🤔

09-Jun-26 17:08:32 70.50 311,003 Unknown* £219.26k

*but above the placing price

GLA

Should boost the investment case. Richard and Chris have both said 2026 is our year. Not just vague future optimism. 2026. They know what’s coming. Richard wouldn’t be taking over his role if there was any doubt in his mind. GLA

Just shows the disconnect in the value of Avacta by its market cap compared to Nuvalent. Both with products in development and both ripe for a takeover. GLA

They wouldn’t want to be out of it over the weekend! 😜